Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.

Publication

Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.

Journal Paper/Review - Jun 13, 2023

Greutmann Matthias, Tobler Daniel, Engel Reto, Heg Dik, Mueller Arndt-Christian, Frenk André, Gabriel Harald, Rutz Tobias, Buechel Ronny Ralf, Willhelm Matthias, Trachsel Lukas, Freese Michael, Ruperti-Repilado Francisco Javier, Valsangiacomo Buechel Emanuela, Beitzke Dietrich, Haaf Philip, Wustmann Kerstin, Schwitz Fabienne, Possner Mathias, Schwitter Juerg, Bouchardy Judith, Schwerzmann Markus, SERVE Investigators

Citation

Greutmann M, Tobler D, Engel R, Heg D, Mueller A, Frenk A, Gabriel H, Rutz T, Buechel R, Willhelm M, Trachsel L, Freese M, Ruperti-Repilado F, Valsangiacomo Buechel E, Beitzke D, Haaf P, Wustmann K, Schwitz F, Possner M, Schwitter J, Bouchardy J, Schwerzmann M, SERVE Investigators. Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE. Eur J Heart Fail 2023; 25:1105-1114.

Type

Journal Paper/Review (English)

Journal

Eur J Heart Fail 2023; 25

Publication Date

Jun 13, 2023

Issn Electronic

1879-0844

Pages

1105-1114

Brief description/objective

In adults with congenital heart disease and systemic right ventricles, progressive right ventricular systolic dysfunction is common and is associated with adverse outcomes. Our aim was to assess the impact of the phosphodiesterase-5-inhibitor tadalafil on right ventricular systolic function.